Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep;34(9):1751-1757.
doi: 10.1007/s11606-018-4795-x. Epub 2019 Jan 16.

Patient Characteristics and General Practitioners' Advice to Stop Statins in Oldest-Old Patients: a Survey Study Across 30 Countries

Affiliations

Patient Characteristics and General Practitioners' Advice to Stop Statins in Oldest-Old Patients: a Survey Study Across 30 Countries

Milly A van der Ploeg et al. J Gen Intern Med. 2019 Sep.

Abstract

Background: Statins are widely used to prevent cardiovascular disease (CVD). With advancing age, the risks of statins might outweigh the potential benefits. It is unclear which factors influence general practitioners' (GPs) advice to stop statins in oldest-old patients.

Objective: To investigate the influence of a history of CVD, statin-related side effects, frailty and short life expectancy, on GPs' advice to stop statins in oldest-old patients.

Design: We invited GPs to participate in this case-based survey. GPs were presented with 8 case vignettes describing patients > 80 years using a statin, and asked whether they would advise stopping statin treatment.

Main measures: Cases varied in history of CVD, statin-related side effects and frailty, with and without shortened life expectancy (< 1 year) in the context of metastatic, non-curable cancer. Odds ratios adjusted for GP characteristics (ORadj) were calculated for GPs' advice to stop.

Key results: Two thousand two hundred fifty GPs from 30 countries participated (median response rate 36%). Overall, GPs advised stopping statin treatment in 46% (95%CI 45-47) of the case vignettes; with shortened life expectancy, this proportion increased to 90% (95CI% 89-90). Advice to stop was more frequent in case vignettes without CVD compared to those with CVD (ORadj 13.8, 95%CI 12.6-15.1), with side effects compared to without ORadj 1.62 (95%CI 1.5-1.7) and with frailty (ORadj 4.1, 95%CI 3.8-4.4) compared to without. Shortened life expectancy increased advice to stop (ORadj 50.7, 95%CI 45.5-56.4) and was the strongest predictor for GP advice to stop, ranging across countries from 30% (95%CI 19-42) to 98% (95% CI 96-99).

Conclusions: The absence of CVD, the presence of statin-related side effects, and frailty were all independently associated with GPs' advice to stop statins in patients aged > 80 years. Overall, and within all countries, cancer-related short life expectancy was the strongest independent predictor of GPs' advice to stop statins.

Keywords: cardiovascular diseases; clinical decision-making; drug therapy; general practitioners; hydroxymethylglutaryl-CoA reductase inhibitors; palliative care.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Reasons for GPs to stop statin treatment in patients over 80 years. The light grey coloured bars represent the proportion of GPs that consider this reason to advise to stop statins in patients over 80 years (multiple reasons could be selected). The black coloured bars represent the proportion of GPs that indicated this reason as the most important reason. Asterisk means life expectancy less than 3 months.

Similar articles

Cited by

References

    1. Chokshi NP, Messerli FH, Sutin D, Supariwala AA, Shah NR. Appropriateness of statins in patients aged ≥80 years and comparison to other age groups. Am J Cardiol. 2012;110(10):1477–81. doi: 10.1016/j.amjcard.2012.06.058. - DOI - PubMed
    1. Morin L, Vetrano DL, Rizzuto D, Calderon-Larranaga A, Fastbom J, Johnell K. Choosing Wisely? Measuring the Burden of Medications in Older Adults near the End of Life: Nationwide, Longitudinal Cohort Study. Am J Med. 2017;130(8):927–36. doi: 10.1016/j.amjmed.2017.02.028. - DOI - PubMed
    1. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623–30. doi: 10.1016/S0140-6736(02)11600-X. - DOI - PubMed
    1. Jansen J, McKinn S, Bonner C, et al. General Practitioners’ Decision Making about Primary Prevention of Cardiovascular Disease in Older Adults: A Qualitative Study. PloS one. 2017;12(1):e0170228. doi: 10.1371/journal.pone.0170228. - DOI - PMC - PubMed
    1. Schuling J, Gebben H, Veehof LJ, Haaijer-Ruskamp FM. Deprescribing medication in very elderly patients with multimorbidity: the view of Dutch GPs. A qualitative study. BMC Fam Pract. 2012;13(7):56. doi: 10.1186/1471-2296-13-56. - DOI - PMC - PubMed

MeSH terms

Substances